• Trendlyne logo
  • Markets
  • Alerts
  • F&O
  • MF
  • Reports
  • Screeners
  • Subscribe
  • Superstars
  • Portfolio
  • Watchlist
  • Insider Trades
  • Results
  • Data Downloader
  • Events Calendar
  • What's New
  • Explore
  • FAQs
  • Widgets
More
    Search stocks
    IND USA
    IND
    IND
    IND
    USA
    • Stocks
    • Futures & Options
    • Mutual Funds
    • News
    • Fundamentals
    • Reports
    • Corporate Actions
    • Alerts
    • Shareholding
    Jenburkt Pharmaceuticals Ltd.
    Jenburkt Pharmaceuticals Ltd.
    29 Jan 2025
    1133.90
    -1.03%
    Jenburkt Pharmaceuticals Q3 Results 2025 on 29 Jan, 2025: profit rise by 20.56% YOY, profit at 6.51 crore and revenue at 36.89 crore
    Jenburkt Pharmaceuticals Q3 Results 2025 on 29 Jan, 2025: profit rise by 20.56% YOY, profit at 6.51 crore and revenue at 36.89 crore
    livemint
    Jenburkt Pharmaceuticals Q3 Results 2025 on 29 Jan, 2025: Revenue increased by 3.45% YoY & profit increased by 20.56% YoY, profit at 6.51 crore and revenue at 36.89 crore
    Copy LinkShare onShare on Share on Share on
    Jenburkt Pharmaceuticals Ltd. is trading above all available SMAs
    logo
    Cipla Ltd.
    29 Jan 2025
    1465.70
    -0.76%
    Cipla Q3 Results 2025 on 29 Jan, 2025: profit rise by 48.74% YOY, profit at 1570.51 crore and revenue at 7072.97 crore
    Cipla Q3 Results 2025 on 29 Jan, 2025: profit rise by 48.74% YOY, profit at 1570.51 crore and revenue at 7072.97 crore
    livemint
    Cipla Q3 Results 2025 on 29 Jan, 2025: Revenue increased by 7.1% YoY & profit increased by 48.74% YoY, profit at 1570.51 crore and revenue at 7072.97 crore
    Copy LinkShare onShare on Share on Share on
    Cipla Ltd. has an average target of 1699.67 from 9 brokers.
    Brokerages divided on Cipla despite strong Q3 earnings beat; buy or sell?
    Business Standard | 29 Jan 2025 6 more
    Cipla expects to end FY25 exceeding margin guidance, beats Q3 earnings estimates
    livemint | 28 Jan 2025
    India's Cipla beats Q3 profit view as strong domestic demand offset weak US sales
    livemint | 28 Jan 2025
    Cipla Q3 result: PAT soars 48.7% to Rs 1,570.5 cr , revenue grows 7.1%
    Business Standard | 28 Jan 2025
    Cipla Q3 result: Profit up 49% at Rs 1,571 cr on strong demand in N America
    Business Standard | 28 Jan 2025
    Cipla Q3 Results: Profit Rises 49%, Beats Estimates
    NDTV Profit | 28 Jan 2025
    Cipla Q3 Results: Net profit jumps 48% YoY to 1,571 crore; revenue improves 8%
    livemint | 28 Jan 2025
    logo
    Ipca Laboratories Ltd.
    28 Jan 2025
    Estimates Miss
    1424.80
    -3.07%
    Buy or sell stocks: Mehta Equities recommends short selling these 3 stocks in a volatile market
    Buy or sell stocks: Mehta Equities recommends short selling these 3 stocks in a volatile market
    livemint
    Buy or sell stocks: Riyank Arora of Mehta Equities recommends short selling Ipca Laboratories Ltd, Sun Pharmaceutical Industries Ltd, and H.G. Infra Engineering Ltd.
    Copy LinkShare onShare on Share on Share on
    Ipca Laboratories Ltd. has an average target of 1815.00 from 3 brokers.
    logo
    Granules India Ltd.
    28 Jan 2025
    Estimates Beat
    530.55
    -0.89%
    Granules India To Offset Gagillapur Facility Delays With New Europe, US Launches
    Granules India To Offset Gagillapur Facility Delays With New Europe, US Launches
    NDTV Profit
    Approvals for four new launches from Granules's US facility have been secured and the fifth approval is awaited.
    Copy LinkShare onShare on Share on Share on
    Granules India Ltd. is trading below its 150 day SMA of 533.5
    logo
    Pfizer Ltd.
    27 Jan 2025
    5613.30
    0.50%
    Pfizer Dodges Challenge to Its Board in Battle With Starboard
    Pfizer Dodges Challenge to Its Board in Battle With Starboard
    livemint
    Pfizer Inc. got a reprieve at least for now in its battle with activist investor Starboard Value LP, according to people familiar with the matter.
    Copy LinkShare onShare on Share on Share on
    Pfizer Ltd. has gained 31.51% in the last 1 Month
    logo
    Biocon Ltd.
    27 Jan 2025
    335.85
    0.07%
    Biocon Board Okays Issuing Of Commercial Papers Worth Rs 570 Crore
    Biocon Board Okays Issuing Of Commercial Papers Worth Rs 570 Crore
    NDTV Profit
    The company informed via filing that the board had given it the go-ahead to secure the funds via short-term, unsecured debt obligations
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors increased from 297 to 305 in Mar 2025 qtr.
    logo
    Torrent Pharmaceuticals Ltd.
    27 Jan 2025
    3174.70
    0.43%
    Torrent Pharma Q3 Results : PL Capital Recommends 'Accumulate' On The Stock, Hikes Target Price Here's Why
    Torrent Pharma Q3 Results : PL Capital Recommends 'Accumulate' On The Stock, Hikes Target Price Here's Why
    NDTV Profit
    Torrent Pharma continues to explore inorganic opportunities which will be key for stock performance, says the brokerage.
    Copy LinkShare onShare on Share on Share on
    Torrent Pharmaceutic.. has an average target of 3725.50 from 5 brokers.
    logo
    Laurus Labs Ltd.
    27 Jan 2025
    609.60
    -0.80%
    Laurus Labs shares down 15% on profit booking post Q3 earnings; Should you buy or sell?
    Laurus Labs shares down 15% on profit booking post Q3 earnings; Should you buy or sell?
    livemint
    Goldman Sachs has retained its Sell' rating on Laurus Labs, setting a price target of 475. The brokerage noted that although the management did not offer specific revenue guidance for FY2025.
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors increased from 237 to 259 in Mar 2025 qtr.
    Laurus Labs Shares Hit Two-Month Low Amid US Foreign Aid Pause, ARV Sales Concerns
    NDTV Profit | 27 Jan 2025 1 more
    Laurus Labs plunges 15% as analysts warn of overvaluation; buy, sell, hold?
    Business Standard | 27 Jan 2025
    logo
    Supriya Lifescience Ltd.
    27 Jan 2025
    724.00
    -3.48%
    Supriya Lifescience plummets 6% after Q3FY25 results; details here
    Business Standard
    Supriya Lifescience share slipped 5.65 per cent at Rs 661.20 a piece on the BSE in Monday's intraday trade despite the pharma company reporting strong quarterly earnings for the financial year 2024-25
    Copy LinkShare onShare on Share on Share on
    Supriya Lifescience .. has an average target of 740.00 from 1 broker.
    logo
    Cohance Lifesciences Ltd.
    27 Jan 2025
    1047.70
    -1.76%
    Suven Pharma looks for 6x increase in revenue by FY35
    Suven Pharma looks for 6x increase in revenue by FY35
    Business Today
    Looking to the future, Suven's Horizon 2 initiative which includes plans to incorporate capabilities in flow chemistry, messenger ribonucleic acid (mRNA), and peptides by fiscal year 2030 is expected to enhance the company's position in advanced drug modalities.
    Copy LinkShare onShare on Share on Share on
    Cohance Lifesciences.. has an average target of 1385.00 from 2 brokers.
    more
    loading
    Logo Trendlyne

    Stay ahead of the market

    Company

    PrivacyDisclaimerTerms of Use Contact Us

    Resources

    Blog FAQsStock Market Widgets

    Copyright © 2025 Giskard Datatech Pvt Ltd